Scholarship Project

Joel Owen

Professor of Pharmaceutical Sciences

16 Results

Book(s), Monograph(s) or Book Chapter(s)

Peer-Reviewed Journal Article(s)

• "CYP2B6 Genotype Based Efavirenz Dose Recommendations During Rifampicin Based Anti-Tuberculosis Co-Treatment for a Sub-Saharan Africa Population.," Pharmacogenomics. (January 2016) (with Mukonzo, J.K., Bisaso, K.R., Ogwal-Okeng, J., Gustafsson, L.L., Aklillu, E.)
• "Characterizing Plasma Albumin Concentration Changes in TB/HIV Patients on Anti-Retroviral and Anti-Tuberculosis Therapy.," In Silico Pharmacology, (2):3. (January 2014) (with Bisaso, K.R., Ojara, F.W., Namuwenge, P.M., Mugisha, A., Mbuagbaw, L., Luboobi, L.S., Mukonzo, J.K.)
• "Pharmacogenetic-Based Efavirenz Dose Modification: Suggestions for an African Population and the Different CYP2B6 Genotypes.," PLOS ONE. (January 2014) (with Mukonzo J.K., Ogwal-Okeng, J., Kuteesa, R.B., Nanzigu, S., Sewankambo, N., Thabane, L., Gustafsson, L.L., Ross, C., Aklillu, E.)
• "Pharmacokinetic Studies in Healthy Subjects for the Development of an Extended-Release Tablet Formulation of Guaifenesin: A 505(b)(2) New Drug Application Approval," (February 2013) (with Lineau Vilson, Jr)
• "Plasma Pharmacokinetics of Two Consecutive Doses of Ferumoxytol in Healthy Subjects," Clinical pharmacology & Therapeutics, 88, 237-242. (August 2010) (with AB Pai, JC Nielsen, A Kausz, P Miller )
• "Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma," Cancer Chemother Pharmacol. (February 2010) (with Melhem M, Passarell JA, D'Andrea D, Darwish M, Kahl B.)
• "Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients," Clinical Pharmacokinetics, Volume 46, Issue 10, 867-884. (October 2007) (with Juan Jose Perez-Ruixo, Peter Zannikos, Sarapee Hirankarn, Kim Stuyckens, Elizabeth A. Ludwig, Arturo Soto-Matos, Luis Lopez-Lazaro and Joel S. Owen )
• "Population Pharmacokinetics of Tigecycline in Healthy Volunteers," The Journal of Clinical Pharmacology, Volume 47, Issue 6, 727-737. (June 2007) (with S. A. Van Wart, B. B. Cirincione, E. A. Ludwig, A. K. Meagher, J. M. Korth-Bradley and J. S. Owen)

Other Article(s)

• "Introduction to Population Pharmacokinetic/Pharmacodynamic Analysis with Nonlinear Mixed Effects Models," (July 2014) (with Jill Fiedler-Kelly)

Presentation(s)

• "Effect of Clinical Study Design on Estimation of Pharmacokinetic Parameters in Pediatric Populations Using Pharmacokinetic Parameters from Adult Populations as Bayesian Priors: Application to Target M" (with G. Bende, J. J. Pérez-Ruixo, and S. Doshi.)
  American Conference on Pharmacometrics, Annual Meeting, Washington, DC. (October 2015)
• "Pharmacogenetic-based pharmacokinetic modeling of plasma and intracellular concentrations of efavirenz on adult Ethiopian HIV and TB/HIV patients." (with A. Habtewold, E. Aklillu, E. Makonnen, W. Amogne, G. Yimer, G. Aderaye, L. Bertilsson, J. Burhenne)
  American Conference on Pharmacometrics, Annual Meeting, Washington, DC. (October 2015)
• "Effect of Clinical Trial Design on the Error Rates for Clearance Estimation in Pediatrics using Adult Bayesian Priors." (with A. Youssef, J. J. Pérez-Ruixo, and S. Doshi.)
  American College of Clinical Pharmacology (ACCP), Annual Meeting, Atlanta, GA. (January 2014)
• "Assessing the Influence of the Log-Transform Both Sides (LTBS) Approach on the Type 1 and Type 2 Error Rates for Clearance Estimation when using Bayesian Priors." (with A. Youssef, J.J. Perez-Ruixo, S. Doshi.)
  Population Approach Group Europe (PAGE), Annual Meeting, Alicante, Spain, . (January 2014)
• "Pharmacokinetics of CW002, a novel neuromuscular blocking agent, in the initial cohorts of a Phase 1 clinical trial." (with P. M. Heerdt , J. K. Malhotra, M. T. Murrell, N. M. Trepanier, C. A. Lien)
  American Association of Pharmaceutical Scientist Annual Meeting, San Antonio, TX. (November 2013)
• "Single-Dose And Steady-State Pharmacokinetics Of Moxduo™, A Dual-Opioid Formulation Containing A Fixed Ratio Of Morphine And Oxycodone" (with Lynn Webster, MK;1 Joel Owen, PhD, Rph;2 Inger Darling, PhD;3 Patricia Richards, MD, Phd;4 Robin Kelen, RN;4 And Warren Stern, PhD4 1lifetree Clinical Research, Salt Lake City, Utah; 2union University, Jackson, Tennessee; 3cognigen Corporation, Buffalo, New York; 4QRXPharma, Inc., Bedminster, New Jersey )
  American Pain Society (APS) Annual Meeting , Baltimore, MD. (May 2010)

Award/Recognition(s)

• Fulbright Specialist, 2013-2017 2013